论文部分内容阅读
为了解ＨＢＶ前Ｃ基因突变与血清“ｅ”抗原和干扰素治疗的临床关系，采用错配碱基ＰＣＲ技术检测ＨＢＶ前Ｃ基因突变，结果发现１４８例“ｅ”抗原阴性病人３４例血清ＨＢＶＤＮＡ阳性；２０例肝硬化，肝癌病人４例ＨＢＶＤＮＡ阳性，全部肝细胞ＨＢＶＤＮＡ阳性；６８例“ｅ”抗原阳性病毒血清前Ｃ基因突变仅为１３２％，５６份抗“ｅ”阳性病毒血清“Ａ”突变频率为７１４％。干扰素治疗对“Ｇ”野生型病毒感染患者优于“Ａ”突变型病毒感染患者。
In order to understand the clinical relationship between the mutation of HBV pre-C gene and serum “e” antigen and interferon therapy, mismatch-based PCR was used to detect the mutation of pre-HBV C gene. The results showed that the serum HBVDNA was positive in 148 cases of “e” negative patients ; HBVDNA was positive in 4 cases of liver cirrhosis and hepatocellular carcinoma and all HBVDNA was positive in all hepatocytes; 68 cases of “e” antigen-positive virus had only 13.2% of pre-serum C gene mutation and 56 cases of “e” positive virus serum “A The mutation frequency was 714%. Interferon treatment was superior to ”A“ mutant virus in patients with ”G" wild-type virus infection.